Preclinical Candidate Development
Building confidence and fostering Success
Mitigating Risks, Maximising Potential
Our commercially attractive package of essential lead optimisation services and non-GLP assays can effectively manage the risk of failure and provide assurance to potential investors for early-stage drug discovery companies seeking funding.
What You Get
Comprehensive In Vitro Pharmacology Screening: Enabling the accurate assessment of your compound's potential efficacy and mechanism of action.
Rigorous ADME Profiling: Offering crucial insights into how your compound behaves within biological systems and its overall profile.
Early Toxicology Evaluation: Helping identify potential safety concerns and mitigate risks before progressing to GLP studies.
Expert Biomarker Analysis: To support efficacy and safety assessments, providing key indicators for successful drug development.
Tailored Pharmacokinetic Profiling and Formulation Testing: Ensuring optimal drug delivery and stability.
Professional Regulatory Consultation and Strategic Guidance: Ensuring your nonclinical submissions meet the required standards.
Our objective is to foster collaboration between developers, their investors and Medicilon's multidisciplinary experts who have completed over 100 candidate development projects.
In collaboration with Medicilon, Hoeford will help you unlock the potential of your drug discovery journey with comprehensive lead optimisation services and non-GLP testing solutions to overcome the challenges of early-stage drug discovery and advance your drug candidates to the next development stage with scientific confidence and a strategy for success.
Medicilon is an expert in developing small molecule drugs, Proteolysis Targeting Chimera (PROTACs), Antibody Drug Conjugates (ADCs), and Antibody-olignucleotide Conjugates (AOCs). We support the vision of developers of these and other novel drug candidates to ensure early-stage lead optimisation drug discovery efforts are geared towards successful funding and development.
With a strong emphasis on risk management and data-driven decision-making, our lead optimisation services can help you navigate early-stage drug development and lead optimisation drug discovery with confidence.
Our team of seasoned experts are dedicated to providing the support and insights needed to reassure potential investors and advance your drug discovery endeavours with a strategic edge. Our comprehensive Candidate Development package includes:
- Target-specific binding assays and functional assays
- Enzyme inhibition assays and activity profiling
- Cell-based assays for assessing compound efficacy and mechanism of action
- Assessment of compound solubility and permeability
- Metabolic stability studies for identifying potential liabilities
- Plasma protein binding assays to understand compound interactions
- Non-GLP acute toxicity studies to assess initial safety profiles
- Early genotoxicity screening to identify potential DNA damage
- Preliminary assessment of reproductive and development toxicity
- Identification of potential biomarkers for efficacy and safety assessment
- Early-stage validation of biomarkers for subsequent GLP studies
- Basic pharmacokinetic assessments for understanding compound behaviour in vivo
- Non-GLP bioavailability studies to estimate potential dose and dosing frequency
- Initial formulation development for optimising drug delivery
- Accelerated stability studies under various conditions to assess potential degradation pathways
- Advisory services for understanding regulatory requirement and pathways
- Assistance with the preparation of nonclinical sections for regulatory submissions
- Comprehensive risk assessment reports highlighting potential areas of concern and proposed mitigation strategies
- Detailed plans for managing and minimising risks during the lead optimisation phase